Abstract

ABSTRACT Cancer is one of the greatest challenges that worry the minds of scientists and threatens human life. Despite the presence of several drugs on the market, their effectiveness remains limited by its resistance. In this research, the Monte Carlo approach was used for QSAR modelling applying the representation of the molecular structure by the SMILES and optimal molecular descriptors. Correlation Ideality (IIC) and Correlation Contradiction Index (CCI)) were introduced as validation parameters to further estimate the predictive ability of the developed models. The statistical quality of the model developed with (IIC) was good compared to those without (IIC). The best QSAR model of the following statistical parameters: (R²train= 0.816, R²valid = 0.825) was selected to generate the activity-increasing and decreasing promoters studied, and these are the basis for the design of seven new candidates as an antiproliferative inhibitory agent. Additionally, the newly designed molecules, the most active compound in the dataset, erlotinib and melphalan as control compounds were docked in the EGFR receptor binding site. The docking results discovered that the proposed candidates had the highest potential and energy affinity. Besides, Lipinski’s Rule of Five, Synthetic Accessibility and ADME/Tox were performed to assess bioavailability and drug-likeness of proposed compounds. In addition, MD simulation accompanied by MM-PBSA analysis discovered that compound A1 and the screened compounds were stable and did not show significant fluctuations throughout the simulation time. Generally, this research showed that the selected model well explains the antiproliferative activity and also that the proposed compounds have high activity, good binding affinity and stable conformation with the reported target protein.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.